Related Experiment Video

Updated: Feb 14, 2026

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.9K

GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes

Victor A Gault1, Christian Hölscher2

  • 1School of Biomedical Sciences, University of University, Coleraine, BT52 1SA, UK.

Peptides
|February 8, 2018
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in treating type 2 diabetes and improving brain function. These agonists reverse cognitive impairments and neuroinflammation, offering benefits beyond glucose control.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is linked to cognitive decline and memory impairment, potentially due to brain insulin resistance.
  • Diabetes negatively impacts brain growth factor signaling, energy utilization, and increases inflammation and apoptosis.
  • Existing diabetes medications like metformin primarily address glycemic control, with limited impact on neurobiological deficits.

Purpose of the Study:

  • To evaluate the therapeutic effects of enzyme-resistant glucagon-like peptide-1 (GLP-1) receptor agonists on cognitive function and neurobiological impairments in type 2 diabetes.
  • To compare the neuroprotective efficacy of GLP-1 receptor agonists with metformin.
  • To investigate the neuroprotective potential of GLP-1 receptor agonists in non-diabetic neurodegenerative conditions.

Main Methods:

  • Administration of GLP-1 receptor agonists to animal models of diabetes-obesity.
  • Assessment of cognitive function, memory formation, and synaptic plasticity.
  • Evaluation of neurotrophic factor signaling, cortical energy utilization, inflammation, and apoptosis.
  • Comparison of GLP-1 receptor agonists with metformin in T2DM models.
  • Clinical studies in non-diabetic patients with neurodegenerative disorders.

Main Results:

  • GLP-1 receptor agonists improved memory formation and synaptic plasticity in diabetes models.
  • Treatment with GLP-1 receptor agonists enhanced neuronal growth and repair, reduced inflammation, apoptosis, and oxidative stress.
  • GLP-1 receptor agonists normalized glycemic control and reversed brain impairments, outperforming metformin.
  • Clinical studies demonstrated neuroprotective effects of GLP-1 receptor agonists in non-diabetic patients, independent of glucose levels.

Conclusions:

  • GLP-1 receptor agonists offer significant therapeutic benefits for type 2 diabetes by improving cognitive function and reversing diabetes-associated neurobiological deficits.
  • The neuroprotective effects of GLP-1 receptor agonists are independent of their glucose-lowering actions, suggesting broader therapeutic applications.
  • GLP-1 receptor agonists represent a promising therapeutic strategy for both T2DM and neurodegenerative disorders.
Keywords:
BrainGIPGLP-1Growth factorsInflammationNeurodegenerationNeurons

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 109:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

10.1K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
527
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
652